Prime Medicine, known for its goal of treating hundreds of diseases with CRISPR, says it's narrowing its focus to two. It ...

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com . Replays of each webcast will ...

Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime ...

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently ...

-- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass.

Prime Medicine, Inc. CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time ...

-- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08 ...